---
document_datetime: 2023-09-21 21:43:42
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/hepsera-epar-procedural-steps-taken-authorisation_en.pdf
document_name: hepsera-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.3790093
conversion_datetime: 2025-12-30 02:30:05.751429
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

The applicant Gilead Sciences International Limited submitted on 26 March 2002 an application for Marketing Authorisation to the European Agency for the Evaluation of Medicinal Products (EMEA) for Hepsera, through the centralised procedure. After agreement by the CPMP on 13 November 2001, this  medicinal  product  has  been  referred  to  Part  B  of  the  Annex  to  Council  Regulation  No  (EEC) 2309/93 of 22 July 1993 as amended.

The Rapporteur and Co-Rapporteur appointed by the CPMP were: Rapporteur: Dr E. Abadie Co-Rapporteur: Dr M. Ainsworth Scientific Advice: The applicant did not seek scientific advice at the CPMP. Licensing status: The product was not licensed in any country at the time of submission of the application. The product was licensed in the United States on 20 September 2002. 2. Steps taken for the assessment of the product · The procedure started on 22 April 2002. · The Rapporteur's first Assessment Report was circulated to all CPMP members on 2 July 2002. The  Co-Rapporteur's  first  Assessment  Report  was  circulated  to  all  CPMP  members  on 24 June 2002. · During  the  meeting  on  23 -  25  July  2002  the  CPMP  agreed  on  the  consolidated  List  of Questions to be sent to the applicant. The final consolidated List of Questions was sent to the applicant on 25 July 2002. · The  applicant  submitted  the  responses  to  the  CPMP  consolidated  List  of  Questions  on 13 September 2002. · The  Rapporteur/Co-rapporteur  circulated  the  joint  Assessment  Report  on  the  applicant's responses to the List of Questions to all CPMP members on 23 October 2002. · The Rapporteur/Co-rapporteur circulated an overall recommendation to all CPMP members on 18 November 2002. · During  the  meeting  on  19-21  November  2002,  the  CPMP,  in  the  light  of  the  overall  data submitted and the scientific discussion within the Committee, issued by consensus a positive opinion  for  granting  a  Marketing  Authorisation  to  Hepsera  on  21  November  2002.  The applicant  provided  the  letter  of  undertaking  of  the  follow-up  measures  to  be  fulfilled  postauthorisation on 21 November 2002. Medicinal Product no longer authorised

<!-- image -->

- The CPMP opinions were forwarded, in all official languages of the European Union, to the European Commission, which adopted the corresponding Decisions on 6 March 2003.